Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial.

Date publication

septembre 2020

Journal

Diabetes & metabolism

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick

Tous les auteurs :
Brandt-Jacobsen NH, Johansen ML, Rasmussen J, Forman JL, Holm MR, Faber J, Rossignol P, Schou M, Kistorp C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32919068

Résumé

As mineralocorticoid receptor antagonists (MRAs) may possess renoprotective effects in type 2 diabetes (T2D), it was decided to investigate the impact of high-dose MRA on prespecified secondary endpoints-namely, change in urinary albumin-creatinine ratio (UACR) and 24-h ambulatory blood pressure-in the MIRAD trial.

Mots clés

High-dose, Mineralocorticoid receptor antagonist, Type 2 diabetes, Urinary albumin excretion

Référence

Diabetes Metab.. 2020 Sep 9;: